EGFR-targeted treatments in patients with metastatic colorectal cancer: Experience of panitumumab.

被引：0
|
作者：
Gumus, Mahmut
Geredeli, Caglayan
Ucar, Mahmut
Kaya, Serap
Demir, Hacer
Unal, Olcun Umit
Degirmenci, Mustafa
Dogu, Gamze Gokoz
Turan, Nedim
Yildirim, Nilgun
Basal, Fatma Bugdayci
Arpaci, Erkan
Karaagac, Mustafa
Harputluoglu, Hakan
Turk, Had Mehmet
Dane, Faysal
Ozkan, Metin
机构：
[1] Istanbul Medeniyet Univ Hosp, Dept Med Oncol, Istanbul, Turkey
[2] Okmeydani Training & Res Hosp, Dept Med Oncol, Istanbul, Turkey
[3] Erciyes Univ, Dept Med Oncol, Kayseri, Turkey
[4] Marmara Univ, Med Oncol, Istanbul, Turkey
[5] Gazi Univ, Fac Med, Med Oncol Clin, Ankara, Turkey
[6] Ataturk Training & Res Hosp, Izmir, Turkey
[7] Tepecik Educ & Res Hosp, Izmir, Turkey
[8] Pamukkale Univ, Denizli, Turkey
[9] Cumhuriyet Univ, Sch Med, Dept Med Oncol, Sivas, Turkey
[10] Ataturk Univ, Dept Med Oncol, Erzurum, Turkey
[11] Ankara Numone Training & Res Hosp, Dept Med Oncol, Ankara, Turkey
[12] Bulent Ecevit Univ, Zonguldak, Turkey
[13] Konya Necmeddin Erbakan Univ, Meram Sch Med, Diyarbakir, Turkey
[14] Inonu Univ, Dept Med Oncol, Fac Med, Malatya, Turkey
[15] Bezmialem Univ, Med Oncol, Istanbul, Turkey
[16] Erciyes Univ, Dept Med Oncol, Kayseri, Turkey
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e15028
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15028
引用
收藏
页数：6
相关论文
共 50 条
  • [41] Erratum to: Integrated molecular dissection of the epidermal growth factor receptor (EGFR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer
    Andrea Sartore-Bianchi
    Katia Bencardino
    Federica Di Nicolantonio
    Federico Pozzi
    Chiara Funaioli
    Valentina Gambi
    Sabrina Arena
    Miriam Martini
    Simona Lamba
    Andrea Cassingena
    Roberta Schiavo
    Alberto Bardelli
    Salvatore Siena
    Targeted Oncology, 2012, 7 : 267 - 267
  • [42] Treatment of metastatic colorectal cancer: focus on panitumumab
    Tay, Rebecca Y.
    Wong, Rachel
    Hawkes, Eliza A.
    CANCER MANAGEMENT AND RESEARCH, 2015, 7 : 189 - 198
  • [43] Panitumumab for the treatment of metastatic colorectal cancer: a review
    Del Prete, M.
    Giampieri, R.
    Faloppi, L.
    Bianconi, M.
    Bittoni, A.
    Andrikou, K.
    Cascinu, S.
    IMMUNOTHERAPY, 2015, 7 (07) : 721 - 738
  • [44] Use of anti-EGFR antibodies (cetuximab and panitumumab) in the treatment of metastatic colorectal cancer in KRAS wild type patients
    Smith, D.
    Bosacki, C.
    Merrouche, Y.
    BULLETIN DU CANCER, 2009, 96 : S31 - S40
  • [45] Role of panitumumab in the management of metastatic colorectal cancer
    Saif, Muhammad Wasif
    Cohenuram, Michael
    CLINICAL COLORECTAL CANCER, 2006, 6 (02) : 118 - 124
  • [46] Mechanisms of resistance to EGFR-targeted drugs: lung cancer
    Morgillo, Floriana
    Della Corte, Carminia Maria
    Fasano, Morena
    Ciardiello, Fortunato
    ESMO OPEN, 2016, 1 (03)
  • [47] The quest to overcome resistance to EGFR-targeted therapies in cancer
    Curtis R Chong
    Pasi A Jänne
    Nature Medicine, 2013, 19 : 1389 - 1400
  • [48] Pharmacokinetics of Irinotecan With and Without Panitumumab Coadministration in Patients With Metastatic Colorectal Cancer
    Yang, Bing-Bing
    Wu, Chi-Yuan
    Chen, Eric
    Infante, Jeffrey R.
    Chen, Alin
    Gao, Bing
    Smith, Brian
    Litten, Jason
    Kennecke, Hagen
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2013, 2 (03): : 205 - 212
  • [49] Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies
    Leto, Simonetta M.
    Trusolino, Livio
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2014, 92 (07): : 709 - 722
  • [50] EGFR-targeted therapy in colorectal cancer: Does immunohistochemistry deserve a role in predicting the response to cetuximab?
    Valentini, Anna Maria
    Pirrelli, Michele
    Caruso, Maria Lucia
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2008, 10 (02) : 124 - 131
12345